Clearly, a comparison of recently Nasdaq uplisted
Post# of 30028
Posted On: 03/15/2015 11:57:47 PM
Re: Daveludlow #18316
Clearly, a comparison of recently Nasdaq uplisted companies will require objectivity and critical thinking skills. The uplisted company target share price would need to take into account the minimum price required for THEIR uplisting. It could be $2, $3, or $4 per share depending on which standard they are using. Amarantus is expect to use the $2 minimum price standard, and this price was specifically mentioned by Gerald in response to a question during one of the conferences last year.
It wouldn't be fair to compare a company that used the $4 minimum price standard, and RS to hit a post-RS price of $6 per share, to one that was using the $2 minimum price standard. Apples to apples.
A better metric would be the difference between the post-RS price and the minimum listing price for the Nasdaq standard used.
It wouldn't be fair to compare a company that used the $4 minimum price standard, and RS to hit a post-RS price of $6 per share, to one that was using the $2 minimum price standard. Apples to apples.
A better metric would be the difference between the post-RS price and the minimum listing price for the Nasdaq standard used.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼